title: Melanoma: a model for testing new agents in combination therapies.
abstract: Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time.
authors.affiliation: Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy. paolo.ascierto@gmail.com
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: Howard Z
authors.initials: HZ
authors.lastname: Streicher
authors.forename: Mario
authors.initials: M
authors.lastname: Sznol
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D008954:Models, Biological; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents
references.citation: N Engl J Med. 2009 Jul 9;361(2):189-91
references.pmid: 19553640
references.citation: Front Biosci. 2006 Jan 01;11:733-42
references.pmid: 16146765
references.citation: Mol Cancer Ther. 2009 Oct;8(10):2872-81
references.pmid: 19825805
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5034-42
references.pmid: 17075123
references.citation: Cell. 2009 May 29;137(5):835-48
references.pmid: 19490893
references.citation: Med Pediatr Oncol. 1982;10(3):251-8
references.pmid: 7045615
references.citation: N Engl J Med. 2005 Nov 17;353(20):2135-47
references.pmid: 16291983
references.citation: Cancer. 2009 Jan 1;115(1):119-27
references.pmid: 19090009
references.citation: J Clin Virol. 2010 Apr;47(4):335-9
references.pmid: 20138803
references.citation: Science. 2009 Mar 27;323(5922):1747-50
references.pmid: 19251594
references.citation: Curr Pharm Des. 2005;11(14):1805-43
references.pmid: 15892677
references.citation: J Clin Oncol. 1997 Jul;15(7):2579-88
references.pmid: 9215828
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7277-90
references.pmid: 19934293
references.citation: Ann Oncol. 2006 Apr;17(4):571-7
references.pmid: 16469753
references.citation: Cancer Res. 2008 Jun 15;68(12):4853-61
references.pmid: 18559533
references.citation: J Clin Oncol. 2007 Jun 1;25(16):e20-1
references.pmid: 17538155
references.citation: J Clin Oncol. 2008 May 1;26(13):2178-85
references.pmid: 18445842
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1600-7
references.pmid: 11896110
references.citation: Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix
references.pmid: 19464601
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3653-4; author reply 3654-5
references.pmid: 18640948
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Cancer Immunol Immunother. 2009 Nov;58(11):1749-59
references.pmid: 19551381
references.citation: Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17777-82
references.pmid: 17968018
references.citation: J Clin Oncol. 1996 Jul;14(7):2083-90
references.pmid: 8683240
references.citation: J Clin Oncol. 2007 May 20;25(15):1955-6
references.pmid: 17513801
references.citation: J Clin Oncol. 1999 Mar;17(3):968-75
references.pmid: 10071291
references.citation: N Engl J Med. 2009 Jul 9;361(2):123-34
references.pmid: 19553641
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5232-7
references.pmid: 17875749
references.citation: Oncologist. 2008;13 Suppl 4:16-25
references.pmid: 19001147
references.citation: Nat Genet. 2009 Oct;41(10):1127-32
references.pmid: 19718025
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304
references.pmid: 20007781
references.citation: J Clin Invest. 2008 Nov;118(11):3660-70
references.pmid: 18924608
references.citation: Cancer Cell. 2005 Oct;8(4):287-97
references.pmid: 16226704
references.citation: J Clin Oncol. 2007 May 1;25(13):1760-4
references.pmid: 17470866
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3073-6
references.pmid: 19451415
references.citation: Cancer Lett. 2009 Oct 8;283(2):125-34
references.pmid: 19217204
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2823-30
references.pmid: 19349552
references.citation: Blood. 2009 Jul 16;114(3):535-46
references.pmid: 19451549
references.citation: J Transl Med. 2009 Oct 14;7:86
references.pmid: 19828018
references.citation: Cancer Res. 2008 Aug 15;68(16):6708-17
references.pmid: 18701495
references.citation: Hematol Oncol Clin North Am. 2009 Jun;23(3):547-64, ix-x
references.pmid: 19464602
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61
references.pmid: 17895472
references.citation: Clin Cancer Res. 2008 Jan 15;14(2):342-6
references.pmid: 18223206
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6747-55
references.pmid: 16170182
references.citation: J Clin Oncol. 2000 Jan;18(1):158-66
references.pmid: 10623706
references.citation: Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4
references.pmid: 18711136
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4738-45
references.pmid: 16966688
references.citation: J Clin Oncol. 2010 Jan 1;28(1):92-8
references.pmid: 19933921
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5650-9
references.pmid: 19858389
references.citation: J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3
references.pmid: 17895470
references.citation: Nature. 2010 Mar 18;464(7287):427-30
references.pmid: 20179705
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295
references.citation: Oncologist. 2008;13 Suppl 4:10-5
references.pmid: 19001146
references.citation: Curr Opin Immunol. 2009 Apr;21(2):233-40
references.pmid: 19304471
references.citation: Nature. 2010 Mar 18;464(7287):431-5
references.pmid: 20130576
references.citation: Curr Pharm Des. 2004;10(16):1907-14
references.pmid: 15180527
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5748-54
references.pmid: 19001327
references.citation: Science. 2009 Dec 18;326(5960):1619
references.pmid: 20019269
references.citation: J Clin Oncol. 1999 Sep;17(9):2745-51
references.pmid: 10561349
references.citation: Pigment Cell Melanoma Res. 2009 Jun;22(3):246-7
references.pmid: 19397758
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900
references.pmid: 17392427
references.citation: Nat Rev Cancer. 2008 Sep;8(9):705-13
references.pmid: 19143055
references.citation: Ann Oncol. 2007 Oct;18(10):1691-7
references.pmid: 17709802
references.citation: N Engl J Med. 1992 Aug 20;327(8):516-23
references.pmid: 1635566
references.citation: Expert Rev Anticancer Ther. 2009 May;9(5):567-81
references.pmid: 19445574
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7116-8
references.pmid: 19934296
references.citation: J Clin Oncol. 2002 Apr 15;20(8):2045-52
references.pmid: 11956264
references.citation: Clin Cancer Res. 2009 Jan 1;15(1):324-9
references.pmid: 19118061
references.citation: Br J Cancer. 2000 Mar;82(6):1158-62
references.pmid: 10735499
references.citation: J Clin Oncol. 1998 May;16(5):1743-51
references.pmid: 9586887
references.citation: Cancer Metastasis Rev. 2010 Mar;29(1):151-70
references.pmid: 20112054
references.citation: Mol Pharmacol. 2009 May;75(5):1231-9
references.pmid: 19246337